(Q39169340)

9 September 2017

title

Pentamerisation of a scFv directed against TRAIL receptor 2 increases its antitumour efficacy (English)

1 reference

9 September 2017

Wei Wang

1

1 reference

9 September 2017

Wen He

2

1 reference

9 September 2017

Lei Wang

3

1 reference

9 September 2017

Ge Zhang

4

1 reference

9 September 2017

Bin Gao

5

1 reference

9 September 2017

publication date

9 April 2013

1 reference

Immunology & Cell Biology

9 September 2017

published in

1 reference

9 September 2017

volume

91

1 reference

9 September 2017

issue

5

1 reference

9 September 2017

page(s)

360-367

1 reference

Antibody fragments: hope and hype

9 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

Di-, tri- and tetrameric single chain Fv antibody fragments against human CD19: effect of valency on cell binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

PEGylation and multimerization of the anti-p185HER-2 single chain Fv fragment 4D5: effects on tumor targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

Thermodynamics and kinetics of the reaction of a single-chain antibody fragment (scFv) with the leucine zipper domain of transcription factor GCN4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

A dual-targeting PDGFRbeta/VEGF-A molecule assembled from stable antibody fragments demonstrates anti-angiogenic activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

Identification and characterization of a new member of the TNF family that induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

The receptor for the cytotoxic ligand TRAIL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

An antagonist decoy receptor and a death domain-containing receptor for TRAIL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

Tetravalent miniantibodies with high avidity assembling in Escherichia coli.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

Pentamerization of single-domain antibodies from phage libraries: a novel strategy for the rapid generation of high-avidity antibody reagents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

"Peptabody": a new type of high avidity binding protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

Multimerization domains for antibody phage display and antibody production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

Sequence plasticity in the antigen-binding site of a therapeutic anti-HER2 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

Humanization of an agonistic anti-death receptor 4 single chain variable fragment antibody and avidity-mediated enhancement of its cell death-inducing activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

Caspase-10 is an initiator caspase in death receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

A human scFv antibody against TRAIL receptor 2 induces autophagic cell death in both TRAIL-sensitive and TRAIL-resistant cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

A novel anti-human DR5 monoclonal antibody with tumoricidal activity induces caspase-dependent and caspase-independent cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

Knockdown of c-FLIP(L) enhanced AD5-10 anti-death receptor 5 monoclonal antibody-induced apoptosis in human lung cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

Directing cancer cells to self-destruct with pro-apoptotic receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

Upregulation of Beclin-1 expression and phosphorylation of Bcl-2 and p53 are involved in the JNK-mediated autophagic cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

Application of phage display to high throughput antibody generation and characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

7 January 2021

Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

7 January 2021

Phase 1b Study of Dulanermin (recombinant human Apo2L/TRAIL) in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

7 January 2021

Assessing individual risk for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

7 January 2021

Phase 1 study of conatumumab, a pro-apoptotic death receptor 5 agonist antibody, in Japanese patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

7 January 2021

COMBODY: one-domain antibody multimer with improved avidity

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

7 January 2021

Crystallization and preliminary crystallographic study of the pentamerizing domain from cartilage oligomeric matrix protein: a five-stranded alpha-helical bundle

1 reference

https://api.crossref.org/works/10.1038%2FICB.2013.10

7 January 2021

Identifiers

DOI

10.1038/ICB.2013.10

1 reference

9 September 2017

1 reference